Time is ticking for investors in the SeaStar Medical Holding Corporation (“SeaStar”) saga as the September 6, 2024 deadline approaches to file a lead plaintiff motion. The lawsuit encompasses the period between October 31, 2022 and March 26, 2024.
If you bore the brunt as a shareholder, don’t dilly-dally – click here to enter the legal fray.
The SeaStar tragedy unfolded when the FDA cast a shadow over the Company’s pediatric Selective Cytopheretic Device (“SCD”). The rejection of SeaStar’s Humanitarian Device Exemption (“HDE”) application sent shockwaves through the stocks on May 9, 2023.
As the tale continued, SeaStar revealed accounting woes on March 27, 2024. This financial fiasco led to a restatement of fiscal standings causing another jolt to shareholders.
Allegedly, throughout the Class Period, SeaStar’s shore was littered with misleading statements and concealed facts about its operations and prospects. The treacherous waters of deficient compliance controls and misleading financial reporting left investors stranded in tumultuous seas.
If you seek solace or to steer the ship as lead plaintiff, the deadline looms large. To navigate these treacherous legal waters, contact the valiant Frank R. Cruz at The Law Offices of Frank R. Cruz. Buckle up or turn a blind eye – both voyages are perilous. Reach out via email, telephone, or visit the website for a lifeline.
For those captivated by updates, flutter over to Twitter: twitter.com/FRC_LAW.
